FDA Guidelines and animal models for osteoporosis - PubMed (original) (raw)
FDA Guidelines and animal models for osteoporosis
D D Thompson et al. Bone. 1995 Oct.
Abstract
The recent FDA Guidelines For Preclinical and Clinical Evaluation of Agents Used in the Treatment or Prevention of Postmenopausal Osteoporosis (1994) delineate specific preclinical animal models to demonstrate the efficacy and safety of new, potential agents for osteoporosis therapy. The Guidelines recommend that agents be evaluated in two animal species, including the ovariectomized (OVX) rat and in a second non-rodent model. We have performed a series of studies to determine whether the recommended OVX rat models, endpoints, and study design adequately address the efficacy and safety of therapeutic agents for the treatment or prevention of osteoporosis. Our study results indicate that the rat OVX model mimics postmenopausal cancellous bone loss when examined over relatively short periods of time. These data illustrate that cancellous bone turnover increases following OVX and this increased bone turnover produces bone loss. Estrogen completely blocks the activation of bone turnover and bone loss. Thus, our data suggest that the rat OVX model in the proximal tibia, distal femur, and lumbar vertebrae mimics conditions in the postmenopausal woman and is suitable for the evaluation of potential therapeutic agents for the prevention of osteoporosis. However, when the duration of the studies extends to 12 months as suggested by the Guidelines, the indices of cancellous bone turnover return to the value of sham controls, although the trabecular bone volume remains lower than that of sham controls in OVX rats. Therefore, it is difficult to determine the effects of potential therapeutic agents on the bone turnover in estrogen deficient conditions.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
- Strain-dependent variations in the response of cancellous bone to ovariectomy in mice.
Iwaniec UT, Yuan D, Power RA, Wronski TJ. Iwaniec UT, et al. J Bone Miner Res. 2006 Jul;21(7):1068-74. doi: 10.1359/jbmr.060402. J Bone Miner Res. 2006. PMID: 16813527 - Effects of droloxifene on prevention of cancellous bone loss and bone turnover in the axial skeleton of aged, ovariectomized rats.
Ke HZ, Chen HK, Qi H, Pirie CM, Simmons HA, Ma YF, Jee WS, Thompson DD. Ke HZ, et al. Bone. 1995 Nov;17(5):491-6. doi: 10.1016/8756-3282(95)00346-2. Bone. 1995. PMID: 8579962 - Comparative effects of droloxifene, tamoxifen, and estrogen on bone, serum cholesterol, and uterine histology in the ovariectomized rat model.
Ke HZ, Chen HK, Simmons HA, Qi H, Crawford DT, Pirie CM, Chidsey-Frink KL, Ma YF, Jee WS, Thompson DD. Ke HZ, et al. Bone. 1997 Jan;20(1):31-9. doi: 10.1016/s8756-3282(96)00313-4. Bone. 1997. PMID: 8988345 - In search of an animal model for postmenopausal diseases.
Thorndike EA, Turner AS. Thorndike EA, et al. Front Biosci. 1998 Apr 16;3:c17-26. doi: 10.2741/a260. Front Biosci. 1998. PMID: 9545440 Review. - [Guidelines for the development of anti-osteoporosis medications].
Avouac B. Avouac B. Therapie. 2003 Sep-Oct;58(5):421-4. doi: 10.2515/therapie:2003068. Therapie. 2003. PMID: 14682190 Review. French.
Cited by
- METTL14-mediated HOXA5 m6A modification alleviates osteoporosis via promoting WNK1 transcription to suppress NLRP3-dependent macrophage pyroptosis.
Tang H, Du Y, Tan Z, Li D, Xie J. Tang H, et al. J Orthop Translat. 2024 Aug 27;48:190-203. doi: 10.1016/j.jot.2024.08.008. eCollection 2024 Sep. J Orthop Translat. 2024. PMID: 39280633 Free PMC article. - The effect of black cohosh extract and risedronate coadministration on bone health in an ovariectomized rat model.
Inselman AL, Masters EA, Moore JN, Agarwal R, Gassman A, Kuijpers G, Beger RD, Delclos KB, Swift S, Camacho L, Vanlandingham MM, Sloper D, Nakamura N, Gamboa da Costa G, Woodling K, Bryant M, Trbojevich R, Wu Q, McLellen F, Christner D. Inselman AL, et al. Front Pharmacol. 2024 Apr 16;15:1365151. doi: 10.3389/fphar.2024.1365151. eCollection 2024. Front Pharmacol. 2024. PMID: 38689663 Free PMC article. - S-Allylmercapto-N-Acetylcysteine (ASSNAC) Attenuates Osteoporosis in Ovariectomized (OVX) Mice.
Bleichman I, Hiram-Bab S, Gabet Y, Savion N. Bleichman I, et al. Antioxidants (Basel). 2024 Apr 17;13(4):474. doi: 10.3390/antiox13040474. Antioxidants (Basel). 2024. PMID: 38671921 Free PMC article. - Impact of osteoporosis and osteoporosis medications on fracture healing: a narrative review.
Chandran M, Akesson KE, Javaid MK, Harvey N, Blank RD, Brandi ML, Chevalley T, Cinelli P, Cooper C, Lems W, Lyritis GP, Makras P, Paccou J, Pierroz DD, Sosa M, Thomas T, Silverman S; Fracture Working Group of the Committee of Scientific Advisors of the International Osteoporosis Foundation, on behalf of the International Osteoporosis Foundation, Société Internationale de Chirurgie Orthopédique et de Traumatologie. Chandran M, et al. Osteoporos Int. 2024 Aug;35(8):1337-1358. doi: 10.1007/s00198-024-07059-8. Epub 2024 Apr 8. Osteoporos Int. 2024. PMID: 38587674 Free PMC article. Review. - 3'-Sialyllactose alleviates bone loss by regulating bone homeostasis.
Baek A, Baek D, Cho Y, Jo S, Kim J, Hong Y, Cho S, Kim SH, Cho SR. Baek A, et al. Commun Biol. 2024 Jan 19;7(1):110. doi: 10.1038/s42003-024-05796-4. Commun Biol. 2024. PMID: 38243116 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources